Literature DB >> 17710158

CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration.

Robert D Loberg1, Chi Ying, Matt Craig, Li Yan, Linda A Snyder, Kenneth J Pienta.   

Abstract

The ability of CCL2 to influence prostate cancer tumorigenesis and metastasis may occur through two distinct mechanisms: 1) a direct effect on tumor cell growth and function, and 2) an indirect effect on the tumor microenvironment by the regulation of macrophage mobilization and infiltration into the tumor bed. We have previously demonstrated that CCL2 exerts a direct effect on prostate cancer epithelial cells by the regulation of their growth, invasion, and migration, resulting in enhanced tumorigenesis and metastasis. Here we describe an indirect effect of CCL2 on prostate cancer growth and metastasis by regulating monocyte/macrophage infiltration into the tumor microenvironment and by stimulating a phenotypic change within these immune cells to promote tumor growth (tumor-associated macrophages). VCaP prostate cancer cells were subcutaneously injected in male SCID mice and monitored for tumor volume, CD68(+) macrophage infiltration, and microvascular density. Systemic administration of anti-CCL2 neutralizing antibodies (CNTO888 and C1142) significantly retarded tumor growth and attenuated CD68(+) macrophage infiltration, which was accompanied by a significant decrease in microvascular density. These data suggest that CCL2 contributes to prostate cancer growth through the regulation of macrophage infiltration and enhanced angiogenesis within the tumor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17710158      PMCID: PMC1939930          DOI: 10.1593/neo.07307

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  15 in total

1.  Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone.

Authors:  Russell S Taichman; Carlton Cooper; Evan T Keller; Kenneth J Pienta; Norton S Taichman; Laurie K McCauley
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

2.  VCaP, a cell-based model system of human prostate cancer.

Authors:  S Korenchuk; J E Lehr; L MClean; Y G Lee; S Whitney; R Vessella; D L Lin; K J Pienta
Journal:  In Vivo       Date:  2001 Mar-Apr       Impact factor: 2.155

Review 3.  Inflammation, a key event in cancer development.

Authors:  Haitian Lu; Weiming Ouyang; Chuanshu Huang
Journal:  Mol Cancer Res       Date:  2006-04       Impact factor: 5.852

4.  CCL2 is a potent regulator of prostate cancer cell migration and proliferation.

Authors:  Robert D Loberg; LaShon L Day; Jason Harwood; Chi Ying; Lauren N St John; Ryan Giles; Chris K Neeley; Kenneth J Pienta
Journal:  Neoplasia       Date:  2006-07       Impact factor: 5.715

5.  Monocyte chemoattractant protein-1 serum levels in patients with breast cancer.

Authors:  Antje Lebrecht; Christoph Grimm; Tilmann Lantzsch; Elisabeth Ludwig; Lukas Hefler; Eva Ulbrich; Heinz Koelbl
Journal:  Tumour Biol       Date:  2004 Jan-Apr

6.  Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations.

Authors:  Jin-Rong Zhou; Lunyin Yu; Luiz F Zerbini; Towia A Libermann; George L Blackburn
Journal:  Int J Cancer       Date:  2004-07-20       Impact factor: 7.396

Review 7.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

8.  Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer.

Authors:  T Valković; K Lucin; M Krstulja; R Dobi-Babić; N Jonjić
Journal:  Pathol Res Pract       Date:  1998       Impact factor: 3.250

9.  Development of the VCaP androgen-independent model of prostate cancer.

Authors:  Robert D Loberg; Lauren N St John; LaShon L Day; Chris K Neeley; Kenneth J Pienta
Journal:  Urol Oncol       Date:  2006 Mar-Apr       Impact factor: 3.498

10.  Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas.

Authors:  Masahiro Ohta; Yasuhiko Kitadai; Shinji Tanaka; Masaharu Yoshihara; Wataru Yasui; Naofumi Mukaida; Ken Haruma; Kazuaki Chayama
Journal:  Int J Cancer       Date:  2002-11-20       Impact factor: 7.396

View more
  101 in total

Review 1.  Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

2.  Macrophage cathepsin K promotes prostate tumor progression in bone.

Authors:  M K Herroon; E Rajagurubandara; D L Rudy; A Chalasani; A L Hardaway; I Podgorski
Journal:  Oncogene       Date:  2012-05-21       Impact factor: 9.867

3.  Monocyte chemotactic protein-1 and CC chemokine receptor 2 polymorphisms and prognosis of renal cell carcinoma.

Authors:  Guan-Xian Liu; Xin Zhang; Su Li; Richard D Koiiche; Jerry H Sindsceii; Haihan Song
Journal:  Tumour Biol       Date:  2013-05-09

4.  Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model.

Authors:  Sofia Halin; Stina Häggström Rudolfsson; Nico Van Rooijen; Anders Bergh
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

5.  A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.

Authors:  Xin Li; Robert Loberg; Jinhui Liao; Chi Ying; Linda A Snyder; Kenneth J Pienta; Laurie K McCauley
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 6.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-14       Impact factor: 7.638

7.  Integrated in silico and 3D in vitro model of macrophage migration in response to physical and chemical factors in the tumor microenvironment.

Authors:  Sharon Wei Ling Lee; R J Seager; Felix Litvak; Fabian Spill; Je Lin Sieow; Penny Hweixian Leong; Dillip Kumar; Alrina Shin Min Tan; Siew Cheng Wong; Giulia Adriani; Muhammad Hamid Zaman; And Roger D Kamm
Journal:  Integr Biol (Camb)       Date:  2020-04-20       Impact factor: 2.192

8.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

Review 9.  Development and translation of novel therapeutics targeting tumor-associated macrophages.

Authors:  David Kosoff; Joshua M Lang
Journal:  Urol Oncol       Date:  2018-11-17       Impact factor: 3.498

10.  Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.

Authors:  Kenneth J Pienta; Jean-Pascal Machiels; Dirk Schrijvers; Boris Alekseev; Mikhail Shkolnik; Simon J Crabb; Susan Li; Shobha Seetharam; Thomas A Puchalski; Chris Takimoto; Yusri Elsayed; Fitzroy Dawkins; Johann S de Bono
Journal:  Invest New Drugs       Date:  2012-08-21       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.